Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Trevena, Inc. logo — company profile

Trevena, Inc.

Founded 2008 United States United States 19 employees Post-IPO Debt Total: $410.93M Biopharma, Biotechnology +2

General Information

Company Name Trevena, Inc.
Founded Year 2008
Location United States United States
Founders / Decision Makers
Team member Team member
Employees 19
Industries Biopharma, Biotechnology, Health Care +1
Funding Stage Post-IPO Debt
Social

BounceWatch is an independent company data service, not affiliated with Trevena, Inc.. To contact Trevena, Inc., visit trevena.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Trevena, Inc. compare?

A PDF of Trevena, Inc. and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Trevena, Inc. soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Trevena, Inc.

Trevena, Inc. is a biopharmaceutical company established in 2008, with a focus on developing and commercializing innovative medications for patients suffering from central nervous system (CNS) disorders. The company operates in the Biopharma, Biotechnology, Health Care, and Pharmaceutical industries and is based in the United States. Their latest investment of $2.00M was in the form of Post-IPO Debt, which took place on 08 July 2024, with the investor being R-Bridge. With a mission centered on addressing unmet medical needs within the CNS space, Trevena presents an intriguing prospect for venture capital consideration.

Funding Rounds & Investors (15)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Debt $2.00M 1
R-Bridge
08 Jul 2024
Post IPO Equity $1.95M -
27 Dec 2023
Post IPO Debt $15.00M -
06 Sep 2023
Post IPO Equity $2.00M -
29 Jul 2022
Post IPO Debt $40.00M 1
CBC Group
CBC Group
31 Mar 2022
Post IPO Equity Undisclosed -
12 Aug 2020
Post IPO Equity $72.90M -
16 Sep 2015
Post IPO Equity $72.88M -
10 Sep 2015
Post IPO Equity $40.00M -
03 Apr 2015
Post IPO Debt $35.00M 2
Square 1 Bank
Square 1 Bank, Oxford Finance LLC
22 Sep 2014

View All 15 Funding Rounds

Trevena, Inc. Alternatives & Competitors

View All Alternatives
Trevena, Inc. vs
MapLight Therapeutics, Inc.
MapLight Therapeutics, Inc. United States

Creating breakthrough innovative therapeutics for serious CNS disorders

Series C
144 employees
Biopharma, Biotechnology
Trevena, Inc. vs
Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. United States

Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for central nerv...

Post-IPO Equity
613 employees
Biopharma, Biotechnology
Trevena, Inc. vs
Cerevel Therapeutics
Cerevel Therapeutics United States

We are a biopharmaceutical company focused on unraveling the mysteries of the brain to treat neurosc...

Post-IPO Equity
373 employees
Biotechnology, Health and Wellness
View all alternatives

FAQ About Trevena, Inc.

Trevena is a biopharmaceutical company focused on developing and commercializing novel medicines for patients with central nervous system (CNS) disorders.
Trevena, Inc. was founded in 2008.
Trevena, Inc. is headquartered in United States.
Trevena, Inc. operates in Biopharma, Biotechnology, Health Care and Pharmaceutical.
Trevena, Inc. has approximately 19 employees.
Trevena, Inc. has completed 15 funding rounds, raising a total of $410.93M. The latest funding stage is Post-IPO Debt.
Top alternatives and competitors to Trevena, Inc. include MapLight Therapeutics, Inc., Axsome Therapeutics, Inc., Cerevel Therapeutics, Neurolixis, Omeros Corporation. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Trevena, Inc. and MapLight Therapeutics, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Trevena, Inc., https://bouncewatch.com/company/trevena, updated 31 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes